Unibest

Pharmaceutical intermediates

Linzagolix Choline Intermediates

7 pharmaceutical intermediates for Linzagolix Choline. Indication: Leiomyoma.

提交项目All intermediates

About Linzagolix Choline

Originator
Kissei Pharmaceutical Co., Ltd.
Indication
Leiomyoma

Available intermediates

7 intermediates currently listed for Linzagolix Choline. Request specifications, documentation or a quotation for any item below.

Linzagolix Choline intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
4-Fluoro-2-methoxyphenol450-93-1//
2,3-Difluoro-6-methoxybenzaldehyde187543-87-9//
5-((2,3-difluoro-6-methoxybenzyloxy)-2-fluoro-4-methoxyaniline935287-59-5//
Dimethyl 4-(phenoxycarbonylamino)thiophene-2,3-dicarboxylate1581731-15-8//
1,2-difluoro-3-((4-fluoro-2-methoxy-5-nitrophenoxy)methyl)-4-methoxybenzene1073435-71-8//
2,3-Difluoro-6-methoxybenzyl Chloride1073435-67-2//
Dimethyl 4-aminothiophene-2,3-dicarboxylate hydrochloride121071-71-4//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodium

Building toward Linzagolix Choline?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →